Emerging Market for Relapsed or Refractory Diffuse Large B-Cell...

Emerging Market for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treatment

Posted 2023-10-31 09:38:39

Market Overview:
Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma affecting B-cells. It accounts for around 30% of non-Hodgkin lymphomas in adults. Standard treatment involves chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. However, about 30-40% of patients either relapse or are refractory to initial therapy.

Market Dynamics:
The relapsed or refractory diffuse large B-cell lymphoma market is driven by two key factors. Firstly, the completion of late-stage clinical trials evaluating promising candidates such as polatuzumab vedotin and lisocabtagene maraleucel which, if approved, will provide newer treatment options. Secondly, the increasing adoption of CAR T-cell therapy despite high costs. Manufacturers are pursuing strategies to lower therapy costs and increase accessibility in order to tap growth opportunities.
Market key trends:
The Relapsed Or Refractory Diffuse Large B Cell Lymphoma Market (RR DLBCL) has been witnessing significant growth driven by rising prevalence of DLBCL and the increasing R&D from prominent pharmaceutical companies for the development of novel treatment options for RR DLBCL. According to GlobeNewswire, DLBCL is one of the most common types of non-Hodgkin lymphoma accounting for around 30% to 35% of cases. In addition, around 30% to 40% of DLBCL patients either relapse or are refractory to first-line treatment. The unmet need for more effective treatment options is expected to create numerous prospective opportunities for players in this market.

SWOT Analysis
Strength: Growing R&D funding and investments from big pharmaceutical companies for the development of novel targeted therapies and immunotherapies.
Weakness: High cost and affordability issues associated with targeted therapies for RR DLBCL treatment.
Opportunity: Increasing prevalence of DLBCL and relapse, refractory patient population that remains underserved. Emergence of combination therapies and personalized medicines.
Threats: Entry of generic competition once key patents expire. Stringent regulatory approvals for new drug candidates.

Key Takeaways
The global relapsed or refractory diffuse large B cell lymphoma market is expected to witness high growth, exhibiting CAGR of 4.3% over the forecast period, due to increasing R&D investments from key players, rising DLBCL prevalence, and growing relapse and refractory patient population.

Regionally, North America is projected to dominate the global market during the forecast period. This is attributed to the presence of major market players, rising healthcare expenditure, and high adoption of advanced treatment options in the region.

Key players operating in the relapsed or refractory diffuse large B cell lymphoma market are MorphoSys U.S. Inc., Bristol-Myers Squibb Company, Karyopharm Therapeutics, Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., Novartis AG, Regeneron Pharmaceuticals, Cellular Biomedicine Group Inc., Genmab A/S, Incyte, AbbVie Inc., Janssen Biotech, Inc., Pfizer Inc., IMV Inc., Overland Pharmaceuticals (CY) Inc., ADC Therapeutics SA, Eagle Pharmaceuticals, Inc., and Adaptive Biotechnologies Corporation.